Abstracts tagged "gout and treatment"

Abstract Number: 899 • 2019 ACR/ARP Annual Meeting
Lack of Effect of Tart Cherry Concentrate Dose on Serum Urate in People with Gout
Lisa Stamp¹, Yuqing Zhang ², Christopher Frampton ³, Jill Drake ³, Peter Chapman ⁴, Stephen Duffull ⁵ and Tuhina Neogi ⁶, ¹University of Otago, Christchurch, Christchurch, Canterbury, New Zealand, ²Massachusetts General Hospital, Boston, MA, ³University of Otago, Christchurch, Christchurch, New Zealand, ⁴Christchurch Hospital, Christchurch, New Zealand, ⁵University of Otago, Dunedin, New Zealand, ⁶Boston University School of Medicine, Boston, MA
Background/Purpose: In small studies, cherries and cherry concentrate have been suggested to reduce serum urate and gout flares. The aims of this study were to…
Abstract Number: 2227 • 2018 ACR/ARHP Annual Meeting
What Should be the Goals of Gout Therapy? a Patient Perspective
Jasvinder A. Singh, Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: In the absence of any available current evidence, our primary objective was to assess the goals of gout treatment from a patient perspective and…
Abstract Number: 1115 • 2017 ACR/ARHP Annual Meeting
Long-Term Adherence to Urate-Lowering Therapy in Gout: Do Not Blame on the Patients
Fernando Perez-Ruiz¹ and Sandra Chinchilla², ¹Rheumatology Division, Hospital Universitario Cruces, Baracaldo, Spain, ²BioCruces Health Research Institute, Barakaldo, Spain
Background/Purpose: adherence to urate-lowering treatment (ULT) in patients with gout is reported to be lower than 50% in the first year and below 20% at…
Abstract Number: 3129 • 2016 ACR/ARHP Annual Meeting
The Pharmacokinetics of Oxypurinol in Patients Treated with Hemodialysis and Allopurinol
Matthew Doogue¹, Dan Wright², Nick Cross³, John Irvine³, Peter T. Chapman⁴, Murray Barclay⁵ and Lisa K. Stamp¹, ¹University of Otago, Christchurch, New Zealand, ²School of Pharmacy, University of Otago, Dunedin, New Zealand, ³Nephrology, Christchurch Hospital, Christchurch, New Zealand, ⁴Christchurch Hospital, Christchurch, New Zealand, ⁵Medicine, University of Otago, Christchurch, New Zealand
Background/Purpose: Allopurinol is recommended as a first-line pharmacologic urate-lowering therapy in gout. Oxypurinol, the active metabolite of allopurinol, is entirely cleared by the kidneys. Oxypurinol…
Abstract Number: 1198 • 2013 ACR/ARHP Annual Meeting
Allopurinol Dose Above Creatinine Clearance Based Dose Is Safe and Effective in Gout – Compliance, Efficacy and Safety At 2 and 3 Years
Nicole Coman-Wright¹, Peter T. Chapman², John L. O'Donnell³ and Lisa K. Stamp⁴, ¹Medicine, University of Otago, Christchurch, Christchurch, New Zealand, ²Rheumatology, Immunology & Allergy, Christchurch Hospital, Christchurch, New Zealand, ³Rheumatology Immunology & Allergy, Canterbury Health Laboratories, Christchurch, New Zealand, ⁴University of Otago, Christchurch, New Zealand
Background/Purpose: Gout is a common form of inflammatory arthritis caused by the crystallisation of uric acid. Sustained reduction of SU below 6mg/dl is critical for…
Abstract Number: 1908 • 2012 ACR/ARHP Annual Meeting
Multinational Evidence-Based Recommendations for Diagnosis and Management of Gout: Integrating Systematic Literature Research and Expert Opinion of a Broad Panel of Rheumatologists in the 3E Initiative
Mariano Andres¹, Francisca Sivera², Alison Kydd³, John Moi⁴, Rakhi Seth⁵, Melonie K. Sriranganathan⁶, Caroline van Durme⁷, Irene AAM van Echteld⁸, Ophir Vinik⁹, Mihir D. Wechalekar¹⁰, Daniel Aletaha¹¹, Claire Bombardier⁹, Rachelle Buchbinder¹², Loreto Carmona¹³, Christopher J. Edwards¹⁴, R. Landewe¹⁵ and Désirée van der Heijde¹⁶, ¹Seccion Reumatologia, Hospital General Universitario de Alicante, Alicante, Spain, ²Sección de Reumatología, Hospital General Universitario de Elda, Alicante, Spain, ³Division of Rheumatology, University of British Columbia, Vancouver, BC, Canada, ⁴Royal Melbourne Hospital, Melbourne, Australia, ⁵Rheumatology, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom, ⁶Rheumatology, St. Mary's Hospital, Isle of Wight, United Kingdom, ⁷Maastricht University Medical Centre, Maastricht, Netherlands, ⁸Atrium Medical Center, Heerlen, Netherlands, ⁹Rheumatology, University of Toronto, Toronto, ON, Canada, ¹⁰Flinders University School of Medicine, Adelaide, Australia, ¹¹Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ¹²Monash Department of Clinical Epidemiology at Cabrini Hospital, Department of Epidemiology and Preventive Medicine, Monash University, Malvern, Victoria, Australia, ¹³Health Sciences School, Universidad Camilo José Cela, Villanueva de la Cañada, Spain, ¹⁴NIHR Wellcome Trust Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom, ¹⁵Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ¹⁶Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: The 3e (Evidence, Expertise, Exchange) Initiative is a multinational collaboration that aims to promote evidence-based medicine in rheumatology. The 2011-12 3e Initiative aimed to…
Abstract Number: 151 • 2012 ACR/ARHP Annual Meeting
Management of Gout Attacks in the Community
Tuhina Neogi¹, Clara Chen², Christine E. Chaisson², David J. Hunter³, Hyon Choi⁴ and Yuqing Zhang⁵, ¹Clinical Epidemiology, Boston University School of Medicine, Boston, MA, ²Boston University School of Public Health, Boston, MA, ³Rheumatology, Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Sydney, Australia, ⁴Division of Rheumatology, Allergy, and Immunology Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁵Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA
Background/Purpose: We previously examined management of gout attacks in the community in 2003-4. Since then, new agents have become available and gout publications have increased,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].